Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04662918 · ClinicalTrials.gov registry record
Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
A clinical trial of GastroIntestinal Bleeding, sponsored by Xingshun Qi.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 20
- Study locations
NCT04662918 is a study of GastroIntestinal Bleeding that is actively recruiting participants, run by Xingshun Qi. The registered enrollment target is 3,000 participants, below the 3,388-participant average among 3 other GastroIntestinal Bleeding trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04662918, a study of GastroIntestinal Bleeding, is actively recruiting participants, sponsored by Xingshun Qi.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.
Conditions Studied
Study Locations (20)
Liaoning
- The Six People's Hospital of Dalian - Dalian
- Air Force Hospital of Northern Theater Command - Shenyang
- General Hospital of Northern Theater Command - Shenyang
- The First Hospital of China Medical University - Shenyang
- The Six People's Hospital of Shenyang - Shenyang
Shaanxi
- Tangdu Hospital, Fourth Military Medical University, - Xi'an
- The First Affiliated Hospital of Xi'an Jiao Tong University - Xi'an
- The Second Affiliated Hospital of Xi'an Jiao Tong University - Xi'an
- Xi'an Central Hospital - Xi'an
Beijing Municipality
- Beijing Youan Hospital, Capital Medical University - Beijing
- The Seventh Medical Center of Chinese PLA General Hospital - Beijing
Pennsylvania
- The Wright Center for Graduate Medical Education, 501 S. Washington Avenue - Scranton
São Paulo
- São Paulo State University (UNESP), Botucatu Medical School - São Paulo
Fujian
- First Affiliated Hospital of Fujian Medical University - Fuzhou
Hubei
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan
Jiangxi
- First Affiliated Hospital of Nanchang University - Nanchang
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04662918
The ClinicalTrials.gov registry entry for NCT04662918 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,388-participant average among 3 other GastroIntestinal Bleeding trials with a reported enrollment target (11% lower). The listed sponsor is Xingshun Qi, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GastroIntestinal Bleeding appearing as the primary indexed condition, and to 0 interventions.
NCT04662918 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Liaoning, Shaanxi, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT04662918 about?
NCT04662918 is a clinical study titled "Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding". Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observationa...
What is the current status of trial NCT04662918?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2022-01-01. Estimated completion is 2025-12.
What conditions does trial NCT04662918 study?
This clinical trial studies the following conditions: GastroIntestinal Bleeding.
Who is sponsoring clinical trial NCT04662918?
This trial is sponsored by Xingshun Qi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04662918 being conducted?
This trial has 20 study locations across Pennsylvania, São Paulo, Beijing Municipality, Fujian, Hubei. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GastroIntestinal Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.